Check Amwill Healthcare IPO share allotment status, listing date and other details

The share allotment for Amwill Healthcare will be finalised later today and investors will get to know about the allotted shares through a lottery basis. Amwill Healthcare IPO secured a subscription of just over 5 times at close.

Investors can check the Amwill Healthcare IPO allotment status through BSE and also via the registrar's website. Firstly, here's how you can do it on BSE

Step 1: Visit the BSE Website (https://www.bseindia.com/investors/appli_check.aspx)


Step 2: Please select the issue name, that is the company's name in the drop down.

Step 3: Enter the application number or PAN number to check the allotment status.

Check Amwill Healthcare IPO allotment through Bigshare Services

Step 1: Visit the Bigshare Services website (https://ipo.bigshareonline.com/IPO_Status.html)

Step 2: Select Amwill Healthcare IPO

Step 3: Enter the PAN details and click search to know the status

Check Amwill Healthcare GMP

Amwill Healthcare GMP has been on the downward trend as is currently at Rs 0, which is a premium of 0% over the issue price. The IPO was offered at a price of Rs 111 and the listing will take place on February 12.

Amwill Healthcare IPO details

Funds raised from the IPO to be used for funding working capital requirements, marketing and brand building activities and general corporate purposes.

Amwill is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled it in developing capabilities, in manufacturing, packaging and distribution.

The core focus of the company is on development of problem solving dermatological, cosmeceutical and aesthetical products. To direct all its efforts towards product formulation and development, it has outsourced key functions such as manufacturing, prototype development and distribution to third parties, for effective management and execution.

The product portfolio is divided into two categories, development and contract manufacturing of generic dermatological solutions; and developing and formulating solutions to specific dermatological problems.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)